Aion Therapeutic Provides Bi-Weekly MCTO Status Update
Aion Therapeutic Inc. (CSE: AION) has provided a bi-weekly update on its management cease trade order (MCTO) issued on August 29, 2024, by the British Columbia Securities Commission. The company is unable to file its 2024 Financial Disclosure by the August 28, 2024 deadline due to complexities associated with the acquisition of Toppen Health, Inc. on December 15, 2023. The BCSC has extended the filing deadline to October 28, 2024, which Aion Therapeutic expects to meet. The company confirms no material changes to the information in the Default Announcement and continues to satisfy the Alternative Information Guidelines set out in NP 12-203.
Aion Therapeutic Inc. (CSE: AION) ha fornito un aggiornamento bisettimanale sul suo ordine di cessazione commerciale del management (MCTO) emesso il 29 agosto 2024 dalla British Columbia Securities Commission. L'azienda è impossibilitata a presentare la propria Dichiarazione Finanziaria 2024 entro la scadenza del 28 agosto 2024 a causa delle complessità associate all'acquisizione di Toppen Health, Inc. avvenuta il 15 dicembre 2023. La BCSC ha prorogato la scadenza di presentazione al 28 ottobre 2024, scadenza che Aion Therapeutic prevede di rispettare. L'azienda conferma che non ci sono cambiamenti materiali alle informazioni nell'Annuncio di Default e continua a soddisfare le Linee Guida sulle Informazioni Alternative stabilite nella NP 12-203.
Aion Therapeutic Inc. (CSE: AION) ha proporcionado una actualización quincenal sobre su orden de cese de comercio de gestión (MCTO) emitido el 29 de agosto de 2024 por la British Columbia Securities Commission. La empresa no puede presentar su Declaración Financiera 2024 antes de la fecha límite del 28 de agosto de 2024 debido a las complejidades asociadas con la adquisición de Toppen Health, Inc. el 15 de diciembre de 2023. La BCSC ha extendido la fecha límite de presentación hasta el 28 de octubre de 2024, plazo que Aion Therapeutic espera cumplir. La empresa confirma que no hay cambios materiales en la información del Anuncio de Default y continúa cumpliendo con las Directrices de Información Alternativa establecidas en la NP 12-203.
Aion Therapeutic Inc. (CSE: AION)은 2024년 8월 29일에 브리티시컬럼비아 증권 위원회에서 발행한 관리 중지 거래 명령 (MCTO)에 대한 2주마다 업데이트를 제공했습니다. 이 회사는 2024년 8월 28일 마감일까지 2024년 재무 공시를 제출할 수 없다고 밝혔습니다. 이는 2023년 12월 15일에 이루어진 Toppen Health, Inc. 인수와 관련된 복잡성 때문입니다. BCSC는 제출 마감일을 2024년 10월 28일로 연장했으며, Aion Therapeutic은 이 기한을 준수할 것으로 예상하고 있습니다. 이 회사는 디폴트 발표의 정보에 중대한 변경 사항이 없음을 확인하고 NP 12-203에 설정된 대체 정보 지침을 계속 충족하고 있습니다.
Aion Therapeutic Inc. (CSE: AION) a fourni une mise à jour bi-hebdomadaire concernant son ordre d'arrêt de commerce de gestion (MCTO), émis le 29 août 2024 par la British Columbia Securities Commission. L'entreprise est dans l'impossibilité de soumettre sa Déclaration Financière 2024 dans le délai du 28 août 2024 en raison des complexités liées à l'acquisition de Toppen Health, Inc. le 15 décembre 2023. La BCSC a prolongé le délai de dépôt jusqu'au 28 octobre 2024, date que Aion Therapeutic s'attend à respecter. L'entreprise confirme qu'il n'y a aucun changement matériel dans les informations de l'Annonce de Défaut et continue de satisfaire les Lignes Directrices sur les Informations Alternatives prévues dans la NP 12-203.
Aion Therapeutic Inc. (CSE: AION) hat ein zweiwöchentliches Update zu seiner Management-Handelsstoppverfügung (MCTO) bereitgestellt, die am 29. August 2024 von der British Columbia Securities Commission ausgestellt wurde. Das Unternehmen ist nicht in der Lage, seine Finanzoffenlegung 2024 bis zur Frist am 28. August 2024 einzureichen, aufgrund der Komplexität im Zusammenhang mit der Übernahme von Toppen Health, Inc. am 15. Dezember 2023. Die BCSC hat die Frist für die Einreichung bis zum 28. Oktober 2024 verlängert, die Aion Therapeutic voraussichtlich einhalten wird. Das Unternehmen bestätigt, dass es keine wesentlichen Änderungen der Informationen im Default-Ankündigung gibt und weiterhin die Alternativen Informationsrichtlinien gemäß NP 12-203 erfüllt.
- BCSC granted an extension for filing 2024 Financial Disclosure until October 28, 2024
- Company anticipates meeting the extended filing deadline
- No material changes to the information in the Default Announcement
- Delay in filing 2024 Financial Disclosure due to complexities with Toppen Health, Inc. acquisition
- Management cease trade order (MCTO) issued by BCSC
- Ongoing accounting and audit process
Toronto, Ontario--(Newsfile Corp. - September 26, 2024) - Aion Therapeutic Inc. (CSE: AION) ("Aion Therapeutic" or the "Company") is providing this bi-weekly update on the status of its management cease trade order issued on August 29, 2024 (the "MCTO"), by its principal regulator, the British Columbia Securities Commission (the "BCSC"), under National Policy 12-203 Management Cease Trade Orders ("NP 12-203"). The Company announced on August 14, 2024 (the "Default Announcement"), that it expected to be unable to file its annual audited consolidated financial statements for the financial year ended April 30, 2024, the related annual management's discussion and analysis and the related CEO and CFO certifications (collectively, the "2024 Financial Disclosure") by the filing deadline of August 28, 2024 (the "Filing Deadline") and last provided an update on the status of the MCTO on September 12, 2024.
As a result of certain complexities associated with the acquisition of Toppen Health, Inc. on December 15, 2023, the accounting and audit process remains ongoing at this time. The BCSC has given the Company until October 28, 2024 to complete its 2024 Financial Disclosure, which the Company anticipates being in a position to meet.
The Company confirms that there are no material changes to the information contained in the Default Announcement. In addition, (i) the Company is satisfying and confirms that it intends to continue to satisfy the provisions of the Alternative Information Guidelines set out in NP 12-203, including the issuance of bi-weekly default status reports in the form of news releases, for as long as the Company remains in default with its 2024 Financial Disclosure; (ii) the Company does not have any information at this time regarding any anticipated specified default subsequent to the default in filing the 2024 Financial Disclosure; (iii) the Company confirms as of the date of this news release, that there is no insolvency proceeding against it; and (iv) there is no other material information concerning the affairs of the Company that has not been generally disclosed.
About Aion Therapeutic Inc.
Aion Therapeutic is a forward-thinking business within the health and wellness sector with a diverse portfolio of intellectual property. With a commitment to innovation and transformative solutions, the Company is poised to drive positive change to redefine the boundaries of health and wellness.
Toppen, a wholly-owned subsidiary of Aion Therapeutic, is a US-based health and wellness company dedicated to delivering state-of-the-art water filtration solutions. With a focus on innovation, affordability, and sustainability, Toppen's water filtration solutions are designed to meet the diverse needs of consumers, businesses, and industries around the world as they strive to provide access to clean and safe water.
For further information, please contact:
Aion Therapeutic Inc.
Graham Simmonds Executive Chair & CEO
(416) 843-2881
DISCLAIMER & READER ADVISORY
This release contains forward-looking information within the meaning of applicable Canadian securities legislation. Expressions such as "anticipates", "expects", "believes", "estimates", "could", "intends", "may", "plans", "predicts", "projects", "will", "would" and other similar expressions, or the negative of these terms, are generally indicative of forward-looking information. Forward-looking statements in this press release include statements regarding: Aion Therapeutic and Toppen's business, business goals and management's expectation on the growth and performance of its business; the preparation and timing of filing the 2024 Financial Disclosure. Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause actual results or events to differ materially from those expressed or implied by such forward-looking information, such as, without limitation, the risk that the parties will be unable to complete, in a timely manner, the 2024 Financial Disclosure.
In addition, the forward-looking information contained in this release is based upon what management believes to be reasonable assumptions. Readers are cautioned not to place undue reliance on forward-looking information as it is inherently uncertain, and no assurance can be given that the expectations reflected in such information will prove to be correct. The forward-looking information in this release is made as of the date hereof and, except as required under applicable securities legislation, the Company assumes no obligation to update or revise such information to reflect new events or circumstances.
The securities of the Company have not been registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This release is issued for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.
The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224766
FAQ
Why did Aion Therapeutic (ANTCF) receive a management cease trade order?
When is the new deadline for Aion Therapeutic (ANTCF) to file its 2024 Financial Disclosure?
What caused the delay in Aion Therapeutic's (ANTCF) 2024 Financial Disclosure filing?
Is Aion Therapeutic (ANTCF) expected to meet the extended filing deadline?
